Potential modifications to the risk-adjustment model used for the Affordable Care Act commercial plans could improve the model and appropriately compensate plans that enroll sicker enrollees.
Potential modifications to the risk-adjustment model used for the Affordable Care Act (ACA) commercial plans could improve the model and appropriately compensate plans that enroll sicker enrollees, according to a new report from Avalere Health. This change would encourage plans to compete based on cost, quality, and health management.
The report, “Evolving the Risk-Adjustment Model to Improve Payment Accuracy in the Individual & Small Group Market,” examines the risk-adjustment program used for the ACA in the commercial market, provides an analysis of the limitations facing the current model, and suggests potential modifications that could improve it.
The ACA created a risk-adjustment program to promote accuracy for health plans by appropriately compensating plans for the financial costs of their enrollees, the report explains. The risk adjustment allows the plans to receive a higher payment for sicker enrollees with costlier care and a lower payment for healthier enrollees, whose care costs less. The goal of the risk-adjustment program is to encourage insurers to compete based on the efficiency and value of their plans, as opposed to attracting healthier enrollees.
“If the risk-adjustment model is inaccurate, then plans that enroll a disproportionate share of sicker enrollees may experience financial losses and exit the market, even if they have priced premiums accurately,” said Tom Kornfield, vice president of Avalere. “By appropriately compensating plans, an accurate model encourages plans to compete based on cost, quality, and health management.”
Limitations to Existing ACA Risk-Adjustment Model
The report identifies 3 main limitations of the existing risk-adjustment model for the individual and small-group market:
The Avalere report concludes that the unique characteristics of the exchange and individual market populations are not being adequately accounted for in the existing risk-adjustment model, so changes should be made to the model to ensure that health plans have an incentive to remain participants in the exchange market.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More